Epidemiological studies have correlated embryonic arsenic exposure with adverse developmental outcomes such as stillbirths, neonatal mortality, and low birth weight.
Introduction
Exposure to arsenic in drinking water can result in developmental toxicity. In humans and mice, arsenic can pass through the placental barrier (Concha et al. 1998; Jin et al. 2006) and in utero exposure of arsenic via the mother's drinking water increases the incidence of neonatal deaths and miscarriages, and reduces birth weight (Concha et al. 1998; Raqib et al. 2009; von Ehrenstein et al. 2006) .
Additionally, arsenic can accumulate in the brain (Jin et al. 2006; Xi et al. 2010) , which may provide a rationale for the correlations between embryonic arsenic exposure and neurological diseases, mental retardation, and lower intelligence quotient scores (Dakeishi et al. 2006; Tsai et al. 2003) . Arsenic trioxide exposure (3 µM) also inhibited neurite outgrowth in Neuro-2a (N2a) cells (Wang et al. 2010) , induced degeneration of neuronal cells in the cerebrum and cerebellum of mice provided 1-2 ppm arsenic trioxide in their drinking water (Piao et al. 2005) , and resulted in thinly myelinated axons in the peripheral sensory nerves of rats given 10 mg arsenite/kg/day in their drinking water (García-Chávez et al. 2007 ).
Arsenic-mediated adverse effects on muscle differentiation have also been reported. For example, exposure of 20 nM arsenite to mouse C2C12 myoblast cells resulted in delayed differentiation into myotubes due to reduced myogenin expression (Steffens et al. 2011) . In rodents, 0.5 and 5 ppm arsenic trioxide given to rodents for 8 weeks suppresses the regeneration of injured muscles (Yen et al. 2010) . Additionally, rats exposed to arsenite or arsenate in utero had reduced locomotor activity and reductions in limb movements (Chattopadhyay et al. 2002; Rodriguez et al. 2002) . Collectively, these results suggest that arsenic acts as a developmental toxicant by affecting the development of the musculature and neurons. However, the molecular mechanisms responsible these multiple adverse outcomes remain largely unknown.
The mouse P19 cell line consists of pluripotent cells capable of differentiating into multiple cell lineages, such as muscles and neurons (McBurney 1993) and appear to recapitulate gene expression patterns during early mouse embryogenesis through similar signaling pathways (Kultima et al. 2010) . One such signaling pathway, the Wnt/β-catenin pathway, plays an important role in somite formation and neural crest development (Geetha-Loganathan et al. 2008; Schmidt et al. 2008) . In stem cells, β-catenin regulates self-renewal and cell fate decisions such that β-catenin-deficient mouse stem cells self-renew rather than differentiate (Ling et al. 2009; Lyashenko et al. 2011) , while overexpression of β-catenin alone triggers stem cells to differentiate into muscles and neurons (Otero et al. 2004; Petropoulos and Skerjanc 2002) . Thus, the use of stem cells is a promising in vitro model to assess cell fate determination (Marikawa et al. 2009 ).
Indeed, it has been shown that exposing human stem cells to 76 nM arsenic downregulated genes indicative of all the three germ layers (Flora and Mehta 2009) . Results from mouse embryonic stem cells indicate that 10 mM arsenic reduced embryoid body formation and inhibited cardiac cell differentiation (Stummann et al. 2008) . However, the molecular mechanisms responsible for arsenic's effects during embryogenesis are not well understood.
Thus, the goal of this study was to determine if arsenic reduced myogenesis and neurogenesis due to altered Wnt/ β-catenin signaling using embryonic stem cells.
Materials and Methods

P19 cell culture and differentiation
The mouse embryonal carcinoma P19 cell line (ATCC, Manassas, VA) was maintained in α-MEM supplemented with 7.5% bovine calf serum (Hyclone, Logan, UT), 2.5% fetal bovine serum (Mediatech, Manassas, VA), 1% L-glutamine, and 1% penicillin/streptomycin (designated as growth medium) at 37°C in a humidified incubator containing 5% CO 2 .
Medium renewal was conducted every 48 hours. To induce differentiation, P19 cells were aggregated by the hanging drop method (Wang and Yang 2008) with some modifications.
Briefly, P19 cells were trypsinized and suspended in differentiation medium (growth medium containing 1% DMSO) with 0, 0.1, 0.5, or 1.0 µM sodium arsenite at a density of 500 cells/20 µl drop. These concentrations correspond to 7.5, 37.5, and 75µg/L arsenic. Human epidemiological studies examining maternal-newborn pairs determined that cord blood arsenic ranged from 2.9-74.6 µg/L, with an average of 15.7 µg/L when mothers drank water averaging 90.5 ppb arsenic (Hall et al. 2007) , while placental and cord blood arsenic levels from babies born in Argentina from an area with 200ppb arsenic in drinking water were 9µg/L in the cord blood and 34µg/kg in the placenta (Concha et al. 1998) . Thus, the arsenic levels used in our study are similar to those that a developing embryo might encounter.
Ninety-six drops of cell suspension were placed on the up-turned inner surface of the lid of a 150mm petri dish, which was inverted and placed on top of the dish containing 10ml of PBS, and incubated for 2 days (day 2). After 2 days, each individual drop was transferred to a 96-well ultralow attachment plate containing 70 µl of fresh differentiation medium with 0, 0.1, 0.5, or 1.0 µM arsenite. After 3 days (day 5), the embryoid bodies were transferred to a 0.1% gelatin coated 48-well plate containing 300 µl of fresh differentiation medium with 0, 0.1, 0.5, or 1.0 µM sodium arsenite. The medium was renewed every 48 hours until cells were harvested.
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When harvesting aggregates on day 5 culture, embryoid bodies from a 96-well plate were collected and combined as one replicate (n=3 per group per day), while for day 9 collection, cells from all wells in a 48-well plate were trypsinized and combined as one replicate (n=3 per group per day). Total RNA were extracted using TRI reagent (Sigma-Aldrich, St. Louis, 
Immunohistochemistry and immunoblotting of differentiated cells
Since the qPCR analysis indicated that gene expression was consistently changed in the 0.5 and 1.0 µM arsenite exposure groups, embryoid bodies exposed with or without 0.5 µM sodium arsenite were prepared as described above for immunohistological analysis. On day 5, embryoid bodies were plated onto 10-cm tissue culture dishes containing 0.1% gelatin coated coverslips. Medium renewal was conducted every 48 hours until the day for immunofluorescence (n=5 per group per day). Cells were fixed with methanol at -20°C for 5 minutes, blocked in 1% bovine serum albumin, 0.1% Triton-X100 in PBS, and incubated Protein extractions and immunoblots were performed according to standard methods. When harvesting aggregates on day 5 culture, embryoid bodies from a 96-well plate were collected and combined as one replicate (n=3 per group per day), while for day 12 collection, cells from all wells in a 48-well plate were trypsinized and combined as one replicate (n=3 per group per day). The same primary antibodies were used as for the immunofluorescence (Tuji: 1:100 dilution; myosin heavy chain: 1:50 dilution). Anti-Tbp antibody (1:1000 dilution, Abcam#818) and anti-Gapdh antibody (1:1000 dilution, IMGENEX # IMG-5019A-1) were used as loading controls. 
Immunohistochemical analysis of embryoid bodies
Embryoid bodies at day 2 and day 5 were exposed to 0 or 0.5µM arsenite as described above.
For day 2 collection, ninety-six drops of cell suspension were harvested from a 150mm petri dish combined as one replicate (n=3 per group per day), while for embryoid bodies on day 5
culture, aggregates from a 96-well plate were collected and combined as one replicate (n=3 per group per day). Once harvested, embryoid bodies were fixed for 24 hours in 10% neutral buffered formalin, dehydrated in graded ethanol, processed, and embedded in paraffin.
Sections (5 µm) were placed on slides, deparaffinized with xylene, and rehydrated in graded ethanol solutions. β-catenin, Pax3, and Nanog staining was carried out in a dark humid chamber for 1 hour, using anti-β-catenin antibody (1:100 dilution, Gene Tex # GTX101254), 
Results
Arsenic represses skeletal muscle and neuronal differentiation in P19 cells
To examine the developmental effects of arsenic exposure on stem cell differentiation, embryoid bodies (EBs) were formed from P19 cells exposed with 0, 0.1, 0.5, or 1.0 µM sodium arsenite. There were no overt morphological differences in EB formation between the control and arsenic exposed cells, and cellular outgrowth from the EBs could be seen on day 7 ( Fig. 1 ). Myoblasts and myotubes, representing about 15% of the total cells, could be identified at day 9 ( Fig. 1) in the control cells. These time frames and percentages are consistent with previous reports (McBurney 1993) . Interestingly, in our experiments, neurons were also formed at day 9 control cells ( Fig.1) , representing 30-40% of the total cells by day 12 (data not shown). However, in the arsenic-exposed cells, the formation of myoblasts, myotubes, and neurons was significantly reduced. While some cells differentiated in the 0.1 µM exposure group, the majority of the outgrowing cells in the 0.5 and 1.0 µM exposures retained an undifferentiated cell-like morphology (Fig. 1) , while a small percentage of the total cell numbers in these two groups remained as embryoid bodies and did not show any signs of outward proliferation and/or differentiation (data not shown).
Arsenic represses β-catenin expression in the differentiating embryoid bodies
Since Wnt/β-catenin signaling plays an important role in the induction of early myogenesis and neurogenesis, the expression of β-catenin during embryoid body formation was examined by immunofluorescence. In the control group of EBs, β-catenin was highly expressed on day 2 and expression levels were reduced on day 5 ( Fig. 2A and C) . However, in arsenic-treated EBs, the expression of β-catenin was much lower than controls at both day 2 and day 5 ( Fig.   2B and D).
Arsenic represses Pax 3 expression in the exterior regions of embryoid bodies
During embryogenesis, Pax3 is an essential transcription factor that regulates skeletal muscle and neuronal differentiation by targeting myogenic and neurogenic transcription factors (Ridgeway et al. 2000) . Moreover, it has been shown that Wnt/β-catenin activates Pax3 expression in P19 cells (Marikawa et al. 2009; Petropoulos and Skerjanc 2002) . To this end, we examined whether repressed β-catenin expression in arsenic-exposed embryoid bodies lead to reduced Pax3 expression. In control cells, Pax3 was highly expressed in the embryoid bodies on day 2 and day 5 (Fig. 3A) and was also expressed in the cells differentiating out 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 from embryoid bodies on day 9 (Fig. 3A) . However, in arsenic-exposed group, Pax3 expression was repressed in the embryoid bodies on day 2 and day 5. And, Pax3 protein was almost absent in the day 9 cells proliferating out from the embryoid bodies in the arsenicexposed group (Fig. 3A) . qPCR corroborated the immunofluorescence, showing a significant reduction in Pax3 transcripts in the 0.1, 0.5, and 1.0µM arsenic-treated groups on day 5 (1.2-, 1.4, and 1.7-fold reduction, respectively) and on day 9 (2.9-, 4.6, and 4.2-fold reduction, respectively) (Fig. 3B ).
Arsenic represses skeletal muscle differentiation by reducing the expression of myogenic regulatory factors
The development of skeletal muscle is regulated by several myogenic transcription factors, including Myf5 and Myo D, which direct the differentiation of muscle progenitors to myoblasts, and then myogenin, which differentiates myoblasts into myotubes (recently reviewed in Yokoyama and Asahara 2011). Thus, the expression Myf5, MyoD, and myogenin from P19 cells exposed with or without arsenic during differentiation was examined. In the control groups, Myf5 and MyoD mRNA transcripts were expressed on day 5 and then were diminished on day 9, with the Myf5 levels reduced to a much greater extent, as would be expected (Fig. 4A ). The expression of myogenin was barely detectable on day 5, but it was induced by 11-fold on day 9 in the control cells (Fig. 4A ). In the arsenic-exposed cells, the expression of Myf5 was not changed in the embryoid bodies at day 5, but was reduced by day 9 cells by ~4.5-fold in the 0.5 µM and 1.0 µM groups. MyoD expression was reduced in a dose-responsive manner in response to arsenite exposure at both day 5 and day 9.
Myogenin expression in the differentiating cells on day 9 was significantly repressed by 10.5-, 80-, and 135-fold in the cells exposed to 0.1 µM, 0.5 µM, and 1.0 µM arsenite, respectively (Fig. 4A) . To confirm these changes, MyoD protein levels were examined on day for the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 control and 0.5 µM arsenite groups. These immunofluorescence studies indicated that MyoD expression was highly repressed in cells exposed to arsenic on day 9 (Fig. 4B) . The reductions in these 3 myogenic transcription factors resulted in suppressed skeletal myotube formation, as indicated by reduced myosin heavy chain expression on day 12 in the cells exposed to 0.5 µM arsenite, as seen by both immunofluorescence (Fig. 4C) and immunoblotting (Fig. 4D) .
Arsenic represses neuronal differentiation by reducing the expression of neurogenic transcription factors
Neurogenin 1 and neurogenin 2 are transcription factors that are expressed in neuronal precursor cells, while NeuroD is the transcription factor that promotes neuronal differentiation into sensory neurons (Howard 2005) . In control cells, the expression of neurongenin 1 and 2 mRNA was at moderate levels in day 5 embyroid bodies, and was then increased in day 9 cells. In contrast, NeuroD expression was not detectable in day 5 EBs, but dramatically increased in the day 9 cells (Fig. 5A) . Arsenite exposure reduced the expression of neurogenin 1 in a dose-responsive manner on both days 5 and 9. Neurogenin 2 expression was not changed in the day 5 cells, but again, arsenite reduced its expression by 2.2-, 3.1-, and 3.8-fold in the 0.1 µM, 0.5 µM, and 1.0 µM arsenite groups, respectively. Finally, arsenic exposure reduced NeuroD expression by 2-fold in the 0.1 µM arsenite-exposed cells, 37-fold in the 0.5 µM exposed cells, and 125-fold in the 1.0 µM exposed cells (Fig. 5A) . The reductions in neurogenin 1, neurogenin 2 and NeuroD transcripts when cells are exposed to arsenite likely decreased the formation of sensory neurons, as shown in Figure 1 . Indeed, the protein expression of the neuronal-specific tubulin Tuj1 in day 12 cells is reduced in the 0.5 µM arsenite exposed cells, as seen by both immunofluorescence (Fig. 5B) and immunoblotting (Fig. 5C ). 
Arsenic increases Nanog expression
In mammals, Nanog is an essential transcription factor that maintains the pluripotency of stem cells (Mitsui et al. 2003) . Many of the outgrowing cells in the arsenite exposures had a morphology similar to P19 cells (Fig. 1) , and were not readily differentiating into myoblasts or neuronal cells. Thus, the effects of arsenite exposure on Nanog transcript levels and protein expression were examined. The qPCR study indicates that Nanog transcripts were increased by 1.4-fold in the 0.5 µΜ EBs and by 1.9-fold 1.0 µM embryoid bodies (Fig. 6A ).
Immunofluorescence staining indicated that Nanog was expressed in both control and 0.5 µM arsenic-exposed EBs at day 5, with its expression being somewhat higher in the arsenicexposed group (Fig. 6B) . However, by days 9 and 12, Nanog is highly expressed in the cells proliferating out from embryoid bodies in the arsenite exposure group, while little Nanog is present in the control cells (Fig. 6B ).
Discussion
The results from the present study using P19 stem cells illustrate that sodium arsenite suppresses skeletal muscle and neuronal differentiation through repressed β-catenin expression. Lowered β-catenin levels leads to reductions in the specific transcription factors needed to convert stem cells into neurons and skeletal myotubes (Figure 7 ). Arsenic is known to affect other signaling pathways. For example, arsenic exposure can cause apoptosis in neuronal cells via the NF-κβ and MAP kinase pathways (Felix et al. 2005; Yen et al. 2011) , can inhibit neuronal outgrowth via the LKB1-AMPK signaling pathway at 3 µM arsenite (Wang et al. 2010) , and inhibits myocyte differentiation and muscle regeneration via the AKT pathway (Yen et al. 2010) . However, these studies were conducted in neuronal and muscle progenitor cells. In stem cells, it appears that one potential mechanism by which low 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 levels of arsenic can repress stem cell differentiation is via the Wnt/β-catenin pathway.
To induce P19 differentiation, DMSO has long been used as a chemical reagent for the induction of mesoderm and endoderm lineages (McBurney 1993) . DMSO can induce neuronal differentiation in neuroblastoma cells (Kimhi et al. 1976) , but this has not been reported in P19 cells. Neurogenin 1overexpression in P19 cells appears to be sufficient for inducing neurons (Kim et al. 2004) , even in the absence of retinoic acid. In the present study, both neurogenin 1 and 2 transcripts were seen during embyroid body formation. Previous studies have demonstrated that co-culturing DMSO-exposed P19 embryoid bodies with the primitive streak mesoderm-like cell line GCLB, could induce neuronal cell differentiation in P19 cells, which was hypothesized to be due to the synergistic action of a Pax3 signal from the GCLB cells and the DMSO treatment (Pruitt 1994) . It is known that Pax3 promotes sensory neuron differentiation in mammals ( Koblar et al. 1999 ) and Pax3 can be induced when P19 cells treated with DMSO (Petropoulos and Skerjanc 2002) . Therefore, it is reasonable to expect that DMSO-induced Pax3 can trigger neurogenin expression in P19 cells.
Immunofluorescence analysis of sectioned embryoid bodies indicates that β-catenin was expressed on day 2 in the control groups. On day 5, the β-catenin levels were greatly reduced after exposure to 0.5 µM arsenite, but are not completely knocked down. Such temporal patterns of β-catenin expression are consistent with previous reports using P19 cells. For example, the level of Wnt/β-catenin was maximal on day 2 of P19 cell differentiation into mesodermal cells, and its expression started to decrease on day 3 (Marikawa et al. 2009 ). In mice, it has been shown that β-catenin is necessary for embryonic development but no longer required for fetal development, such as the differentiation of myoblasts (Hutcheson et al. 2009 ). Although it is not completely absent as in a knockout mouse model, the repressed β- catenin expression in our P19 cells exposed to arsenite indicates that Wnt signaling was likely repressed in the early stage of embryoid body development. This may be the initial regulatory mechanism responsible for the reduced skeletal muscle and neuronal cell formation on day 9 after arsenic exposure. Indeed, it has been shown that β-catenin can directly activate Myf5, as two β-catenin responsive elements in Myf5 promoter are essential for mouse myotomal development (Borello et al. 2006) , and can also induce the expression of neurogenin 2 (Hirsch et al. 2007 ).
Recently, altered Wnt/ β-catenin signaling has been reported after arsenic exposure. catenin reduction can be regulated by overexpressing nucleoredoxin, which is a thioredoxin family member, in HEK293 cells and in Xenopus (Funato and Miki 2010) . Since arsenic toxicity has been related to the induction of ROS (Piao et al. 2005) , arsenic-induced reactive oxygen species may play a role in the reduction of β-catenin expression in P19 cells.
During differentiation, β-catenin-signaling triggers myogenesis and neurogenesis through Pax3 (Petropoulos and Skerjanc 2002; Ridgeway et al. 2000) . In the arsenite-exposed embryoid bodies, Pax3 transcript levels were lowered on day 5, and its protein expression was lowered on both day 2 and day 5, likely due to reduced β-catenin levels. It is interesting that the spatial expression of Pax3 differed between control and arsenite-exposed cells. In control cells, Pax3 is highly expressed at the edges of the embryoid bodies and is later 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 expressed in the differentiating cells on day 9. In the arsenic-exposed cells, Pax3 is expressed in the interior of the embyroid body, but its expression is extremely low at the edges of embryoid bodies. By day 9, Pax3 expression is almost absent in the differentiated regions from arsenic-exposed embryoid bodies. In contrast, on day 9, Pax3 is expressed in the differentiated and differentiating outgrowing cells where the skeletal myotubes and neurons are formed on day 9 and day 12. This reduced expression is also confirmed by qPCR data.
In the nervous system, Pax3 upregulates neurogenin 2, which plays a key role in the specification of neuronal subtypes, neural crest development, and sensory neurogenesis (Nakazaki et al. 2008) . In skeletal muscle progenitors, Pax3 upregulates Myf5, MyoD, and myogenin (reviewed in Buckingham 2007) . As a result of the reductions in Pax3 expression, these key transcription factors for muscle and neuronal differentiation were also repressed by arsenic exposure in this study in a dose-responsive manner. Moreover, Pax7, which has also been suggested to play a key role in muscle and neuronal cell fate determination in mice (Jostes et al. 1990) , is reduced by 3.2-, 8.2-, and 4.6-fold in the 0.1, 0.5, and 1.0 µM arseniteexposed cells on day 9 of embryoid body differentiation (data not shown). In contrast, Nanog expression, which maintains the pluripotency of stem cells (Mitsui et al. 2003) , is between 1.4-to 1.9-fold higher in the arsenic-exposed cells. These results indicate that, rather than undergoing skeletal and neuronal lineages, the majority of arsenic-exposed cells were maintained in the self-renewal status, thereby leading to the reduced formation of skeletal muscles and neurons.
In conclusion, our results indicate that 0.5 µM sodium arsenite suppresses skeletal muscle and neuronal formation from P19 mouse embryonic stem cells likely due to repressed Wnt/β-catenin signaling, which leads to reductions in myogenic and neurogenic transcription factor 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 expression. This study provides insights into how arsenic exposure affects skeletal and neuronal differentiation during embryogenesis, and highlights the utility of using embryonic stem cells to assess cell fate determination.
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Each sample was run in triplicate (n=3), results were normalized to Gapdh, and are expressed as the number of molecules per 100ng cDNA. ANOVA followed by Tukey's (p<0.05) was performed to determine statistical differences between concentrations (*) and between days (#) (A). Differentiated cells from embryoid bodies exposed with or without 0.5µM arsenite on day 9 were fixed and MyoD expression was examined by immunofluorescence (B). Cells grown out to day 12 were fixed and myosin heavy chain expression was examined by immunofluorescence (C). Dashed lines indicate the location of an embryoid body (EB).
Pictures are representative examples from 198 independent embryoid bodies/time point/group.
Myosin heavy chain protein expression was examined by immunoblotting, using embryoid bodies exposed with or without 0.5µM arsenic on day 12. Gapdh was used as a loading control (D). Neurogenin1, Neurogenin 2, and NeuroD mRNA expression on day 5 and day 9 of cells derived from embryoid bodies after exposure to 0, 0.1, 0.5, and 1.0µM arsenite were quantified by qPCR. Each sample was run in triplicate (n=3), results were normalized to Gapdh, and are expressed as the number of molecules per 100ng cDNA. ANOVA followed by Tukey's (p<0.05) was performed to determine statistical differences between 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 concentrations (*) and between days (#) (A). Differentiated control cells and cells exposed to 0.5µM arsenite were fixed on day 12, and Tuj1 expression was examined by immunofluorescence (B). Pictures are representative examples from 198 independent embryoid bodies/time point/group. Tuj1 protein expression was examined by immmunoblotting, using embryoid bodies exposed with or without 0.5µM arsenic on day 12, with Gapdh used as a loading control (C).
Fig 6. Arsenic increases Nanog expression during differentiation.
Nanog mRNA expression in day 5 embryoid bodies after exposure to 0, 0.1, 0.5, and 1.0µM arsenite was quantified by qPCR. Each sample was run in triplicate (n=3), results were normalized to Gapdh, and are expressed as the number of Nanog molecules per 100ng cDNA.
ANOVA followed by Tukey's (p<0.05) was performed to determine statistical differences (*) (A). P19 cells, cultured with or without 0.5µM sodium arsenite, were aggregated for 5 days, and then differentiated out to day 9 and 12. Embryoid bodies were harvested on day 5 and embedded with paraffin, while differentiated cells were fixed on days 9 and 12. Nanog During P19 aggregation, β-catenin expression was repressed by arsenic exposure on day 2.
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